Navigation Links
Cynvenio Announces ClearID® Commercial Distribution Agreements for Israel, Greece, Argentina and South Korea
Date:6/14/2017

Cynvenio Biosystems, Inc. a leader in LiquidBiopsy® cancer diagnostics and personalized medicine technology, today announced four new distribution agreements for Cynvenio’s ClearID line of blood tests that support targeted treatment selection and patient monitoring over the cancer care cycle. The commercial agreements will make ClearID available immediately in Israel, Greece, Argentina, and South Korea.

Pronto Diagnostics is a provider of molecular diagnostic products and services in Israel, representing a variety of technologies in the field of genetic and molecular diagnostics.

Karyo is a private diagnostics laboratory in Greece providing genetic testing services supported by a qualified staff of molecular biologists, certified cytogeneticists, and clinical geneticists.

ProgeniTest is a leading genetic analysis service lab in Argentina offering more than 3,500 different tests and support services to help clients select tests and interpret results.

Bio-Medical Science Co. is an established supplier of life sciences research and diagnostics products in South Korea with offices in Seoul and Daejeon and a distribution center in Gimpo.

Cynvenio’s ClearID is designed for patients undergoing treatment for cancer and those who require follow-up testing at regular intervals after completion of therapy. Currently, there are ClearID sequencing panels optimized for breast, colon and lung cancer and a ClearID test for PD-L1 expression. These tests use molecular analysis to rapidly and precisely generate real-time information on cancer cell activity. Using a normal blood draw, ClearID detects the presence of scarce populations of cancer cells in the bloodstream and identifies gene alterations known to signal resistance to therapy.

Based on Cynvenio’s patented LiquidBiopsy® approach to tumor monitoring, ClearID tests analyze a combination of DNA from circulating tumor cells (CTC), cell-free DNA (cfDNA), and germline DNA (gDNA). This multi-sourced DNA analysis produces direct insights into the progression of the primary tumor and the metastatic disease process, while increasing specificity by using germline DNA as a built-in control to eliminate biological and instrument noise.

“We are pleased to announce these partnerships as we continue to expand our global presence,” said Humberto Huerta, Cynvenio Chief Commercialization Officer. “All of these distributors are leaders in genomic testing and we look forward to working together to make ClearID available to more physicians and patients around the world.”

“All of our testing partners can leverage Cynvenio’s CLIA/CAP lab in California to quickly gain traction in their home markets with minimal investment, which is a huge benefit to the doctors and patients they serve,” said André de Fusco, Cynvenio’s CEO. “Later, if/when they desire, they have the option to expand locally by installing our automated LiquidBiopsy platforms in their own labs and bring the whole testing process under their control - it’s the best of both worlds.”

About Cynvenio Biosystems, Inc.

Cynvenio’s LiquidBiopsy testing technology is leading the way to more affordable and clinically actionable precision medicine strategies for cancer patients.  Among the company’s breakthroughs is its line of ClearID® tests for greatly improved cancer detection and monitoring via a patient-friendly blood draw, and a suite of proprietary, distributable LiquidBiopsy® platforms and consumables for deployment in hospitals and third party diagnostic labs. Cynvenio is based in Westlake Village, California. For more information, please visit http://www.cynvenio.comhttp://www.clearidmonitoring.com, and http://www.liquidbiopsy.com.

LiquidBiopsy® and ClearID® are registered trademarks of Cynvenio Biosystems, Inc.

Read the full story at http://www.prweb.com/releases/2017/06/prweb14424328.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. Cynvenio’s LiquidBiopsy® Platform-Derived Research Data to be Presented at the 2017 ASCO Annual Meeting, June 2-June 6, 2017 in Chicago, Illinois
2. Cynvenio Research Highlights Need for Longitudinal Monitoring of Triple Negative Breast Cancer Patients
3. Cynvenio Releases ClearID® Lung Cancer: a Highly-Targeted Genomic Blood Test for Lung and Thoracic Cancer Patients
4. Cynvenio and TME Research Announce Neoadjuvant Breast Cancer Monitoring Study (NEAT)
5. Cynvenio Releases Two New High Recovery LiquidBiopsy® CTC Capture Kits at 2017 AACR Annual Meeting in Washington, DC.
6. Cynvenio Biosystems Announces Expansion of Payer Network with Addition of Blue Cross Blue Shield of Illinois
7. Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test
8. Cynvenio and CollabRx Announce Partnership for Cancer Molecular Diagnostics
9. Cynvenio Biosystems Receives CLIA Certification for its Genomic Sequencing Laboratory
10. Cynvenio Biosystems to Present Clinical Data on Mutational Analysis of LiquidBiopsy® Tumor Samples at the 2013 ASCO Annual Meeting
11. ACEA Biosciences Announces Successful Completion of Phase I Clinical Study of Novel Autoimmune Disease Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... New York, NY (PRWEB) , ... August 15, 2017 , ... ... for the first time on Immuno-Oncology 360° (IO360°) programming through a series of upcoming ... to be held February 7-9, 2018, at The Roosevelt Hotel in New York City. ...
(Date:8/14/2017)... ... August 14, 2017 , ... ... antibodies. Key researchers in the antibody community have recently come together to address ... antibodies in the laboratory. , The team at Thermo Fisher ...
(Date:8/11/2017)... , Aug. 11, 2017  Market ... New York Times article regarding the telemedicine ... according to Kalorama Information.  The article, ... for That"  used information from Kalorama ... Monitoring & Telemedicine Market  (Sleep, Diabetes, ...
(Date:8/11/2017)... ... August 11, 2017 , ... “There is an ... natural alternatives to synthetic ingredients,” said Matt Hundt, President of Third Wave Bioactives. ... manufacturing presence and know-how of Biorigin will allow us to bring truly novel ...
Breaking Biology Technology:
(Date:4/11/2017)... Florida , April 11, 2017 ... a security technology company, announces the appointment of independent Directors ... Bendheim to its Board of Directors, furthering the company,s ... ... of NXT-ID, we look forward to their guidance and benefiting ...
(Date:4/5/2017)... 2017  The Allen Institute for Cell Science today ... one-of-a-kind portal and dynamic digital window into the human ... first application of deep learning to create predictive models ... and a growing suite of powerful tools. The Allen ... future publicly available resources created and shared by the ...
(Date:4/5/2017)... April 4, 2017 KEY FINDINGS ... expand at a CAGR of 25.76% during the forecast ... the primary factor for the growth of the stem ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem cell ... application, and geography. The stem cell market of the ...
Breaking Biology News(10 mins):